Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ARCTURUS THERAPEUTICS HOLDINGS INC. Arcturus Therapeutics Holdings Inc. Stock price
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 23.79 USD | -0.96% | -4.34% | +40.27% | |
Financials (USD)
| Sales 2023 * | 174M | Sales 2024 * | 159M | Capitalization | 636M |
|---|---|---|---|---|---|
| Net income 2023 * | -40M | Net income 2024 * | -85M | EV / Sales 2023 * | 3,66x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 3,99x |
| P/E ratio 2023 * | -16,2x | P/E ratio 2024 * | -8,06x | Employees | 170 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 91.09% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.96% | ||
| 1 week | -4.34% | ||
| Current month | -0.63% | ||
| 1 month | +22.63% | ||
| 3 months | -24.62% | ||
| 6 months | -16.20% | ||
| Current year | +40.27% |
1 week
22.70
25.30
1 month
17.5226.71
Current year
14.2137.75
1 year
14.2137.75
3 years
11.70124.00
5 years
4.11129.71
10 years
4.11129.71
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 51 | 2013 |
Andrew Sassine
DFI | Director of Finance/CFO | 58 | 2019 |
| Chief Tech/Sci/R&D Officer | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 82 | 2019 |
James F. Barlow
BRD | Director/Board Member | 64 | 2018 |
Peter Farrell
CHM | Chairman | 80 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.90% | 2 M€ | +1.46% | - | |
| 2.82% | 1,356 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 23.79 | -0.96% | 329,477 |
| 23-12-07 | 24.02 | +2.47% | 241,560 |
| 23-12-06 | 23.44 | +2.09% | 1,410,750 |
| 23-12-05 | 22.96 | -4.29% | 259,824 |
| 23-12-04 | 23.99 | -3.54% | 264,903 |
Delayed Quote Nasdaq, December 08, 2023 at 04:00 pm EST
More quotes
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Calendar
2024-01-09
- JPMorgan Healthcare Conference
Trading Rating :
Investor Rating :
ESG Refinitiv :
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.79USD
Average target price
63.5USD
Spread / Average Target
+166.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.27% | 636 M $ | |
| +70.40% | 41 313 M $ | |
| +5.07% | 39 289 M $ | |
| -55.28% | 30 625 M $ | |
| -27.34% | 27 758 M $ | |
| +40.26% | 22 431 M $ | |
| -28.45% | 21 339 M $ | |
| +4.49% | 17 693 M $ | |
| -13.10% | 11 356 M $ | |
| -17.58% | 10 803 M $ |
